Movement Alert｜BIOCYTOGEN-B Falls 5.2% in Regular Trading, Shares Extend Pullback Ahead of October 29 Results Board Meeting

Market Focus10-26

On October 26, BIOCYTOGEN-B fell 5.2% in Regular Trading, trading at HK$39.32, with turnover of HK$33.68 million.

The most recent public update tied to the stock's weakness is that shares were still in a results-disclosure window ahead of the October 29 board meeting to review the nine-month results and arrange their release, while the stock had already been in pullback mode in recent sessions.

Previously disclosed first-half results remained strong, with revenue of RMB941 million, up 51.60% year on year, net profit attributable to shareholders of RMB241 million, up 402.29%, and non-recurring-adjusted net profit of RMB197 million, up 591.53%. Separate filings also showed share capital remained unchanged through September, while recent shareholder position changes included a fund increasing its stake to 9.05% on October 7 after an earlier reduction.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment